Madrigal Pharmaceuticals Inc

MDGL

Equity

ISIN null / Valor 33395434

NASDAQ (2026-03-31)

USD 523.47+3.59%

Madrigal Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Madrigal Pharmaceuticals Inc. is a biopharmaceutical entity focused on the development of innovative treatments for nonalcoholic steatohepatitis (NASH), a condition also referred to as metabolic dysfunction associated steatohepatitis (MASH). The company has made significant strides in this therapeutic area, with its first therapy receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults exhibiting moderate to advanced liver fibrosis, which corresponds to stages F2 to F3 fibrosis, a critical subset of the NASH patient population. Furthermore, Madrigal is advancing its research and development efforts by conducting a Phase 3 trial aimed at evaluating the efficacy of its therapy in treating NASH with compensated cirrhosis, demonstrating its commitment to addressing the unmet medical needs within this patient community.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

58.0%1Y

116%3Y

348%5Y

Performance

48.5%1Y

56.2%3Y

82.1%5Y

Volatility